Minoryx licenses a patent from IDIBELL of a product to treat X-linked Adrenoleukodystrophy
The repositioned drug candidate has shown excellent efficacy in invivo models.
Minoryx has signed an in-licensing agreement with the Catalan research institute IDIBELL of a patent for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare and life threatening neurodegenerative disease, which has no effective treatment.
The Neurometabolic Diseases group led by ICREA Dra. Aurora Pujol, has developed an animal model to study this disease. Studies using this model have demonstrated that a repositioned drug candidate may be effective against X-linked adrenoleukodystrophy.
The agreement has been managed by the Technology Transfer Office of IDIBELL and it represents an opportunity not only to get this inventions into the market and patients, but also to initiate a partnership of trust between Minoryx and IDIBELL in developing new solutions to improve the quality of life of patients with adrenoleukodystrophy.